SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-116642
Filing Date
2024-10-23
Accepted
2024-10-23 16:09:55
Documents
13
Period of Report
2024-10-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20241023.htm   iXBRL 8-K 42468
2 EX-99.1 vktx-ex99_1.htm EX-99.1 240489
3 GRAPHIC img201808844_0.jpg GRAPHIC 13142
  Complete submission text file 0000950170-24-116642.txt   442975

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20241023.xsd EX-101.SCH 30914
15 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20241023_htm.xml XML 4719
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 241389314
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)